• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Belgium·Healthcare·REMI
Share

Remedent, Inc. Stocks

$ 0Last Updated 11.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 13997

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Remedent, Inc., operating through its various subsidiaries, specializes in the research, development, manufacturing, and distribution of products for both oral hygiene and aesthetic dentistry. The company's core offerings include professional-grade dental veneers and teeth whitening systems, designed for use by dental practitioners as well as for over-the-counter purchase by consumers. Its innovative product portfolio features River8, a pre-fabricated veneer solution that assists dentists in achieving optimal tooth alignment with minimal patient tooth reshaping. Additionally, Remedent supplies GlamSmile veneers, which are exceptionally thin shells bonded to the front surfaces of a patient's teeth. Beyond physical products, the company offers a suite of digital tools and services aimed at enhancing dental practice operations. These include the SmileMe Mirror, an integrated marketing concept that enables quick smile consultations in about ten minutes; SmileSketch, simulation software capable of creating visual previews of potential aesthetic results; and various "Treatment Pages" designed to explain the advantages of specific dental procedures. Furthermore, Remedent provides the Condor, an advanced intra-oral 3D scanning device. The company's expertise also extends to dental implant technologies and related treatment methodologies. Remedent distributes its products to dental professionals in nearly 30 countries, spanning regions such as Asia, Europe, the Middle East, Canada, and the United States, utilizing both its internal sales team and third-party distributors. Founded in 1986, the company's corporate headquarters are located in Ghent, Belgium.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026